More Videos
|
CNBC'S MOST SHARED
- A Goldman Trading Scandal?
- Rich People With A Death Wish
- The Threat of Ballooning Pensions
- Lehman CEO: Firm Deserved Bailout or 'Wind Down'
- SEC May Reinstate Rules for Short-Selling Stocks
- Market's Monday Blues
- Is Andy’s Mojo Back? We Asked Him
- Your First Move For Monday July 6th
- China Launches Major Step to Yuan Internationalization
- 5-Star Manager's 5 Top Stocks
- Hey, What's Up Doc?
- Busch: Summertime Blues Hits Investors
- Chadwick: Recession and Scandals Pave the Way for Romney 2012
- Art Cashin: The S&P's 'Head and Shoulders' Number
- Michael Jackson: Death And Taxes
- Is Andy’s Mojo Back? We Asked Him
- GM A Step Closer To Exiting Bankruptcy
- Schork Oil Outlook: The Fear Trade
- Russian President Calls Obama Summit 'Important Step'
- Goldman Sees No Harm From Computer Programmer
- Farrell: Don't Head For The Exits Yet
- Justice Dept Said to Be Looking At Telecom Giants
- Lehman CEO: Firm Deserved Bailout or 'Wind Down'
- GM to Get Final $20 Billlion From US This Year
- US Service Sector Has Best Showing In Months
- Tribune, Cubs Deal Agreed In Principle
- Facebook Director Sees 'Billions' in Revenue in 5 Years
RSS FEED
Text Size 
 |
In my mail slot this morning I found a complimentary copy of a new version of the "Merck Manual."
Thanks, Merck[MRK
Loading...
()
].
It'll be put to good use here in the CNBC newsroom where co-workers seem to think that just because my producer and I cover pharma that we're able to diagnose their or their loved ones' ailments, recommend the right drug and get them free samples.
Needless to say, but I'll say it anyway, we don't do any of that. This edition is called, "The Merck Manual of Patient Symptoms" and unlike the popular, thick hardcover one that's been published across three centuries, this new one comes in a handy-dandy paperback.
As the press release that came with it says, "Compact enough to carry in a lab coat pocket, the paperback helps health care practitioners, particularly those who are newcomers to clinical diagnosis, understand and evaluate a wide range of symptoms."
Excuse me? I don't know about you, but I don't think I want to see a nurse practitioner, physician assistant or med student at a teaching hospital whip out a "Merck Manual" to figure out what's wrong with me. Can you say, "I want a second opinion"?
Meantime, investors are trying to figure out what's ailing Merck. The stock hit another new intra-day low this morning of around 30-and-a-half bucks. MRK is one of a handful of Dow components not participating in today's rally--at least, not yet. (Pfizer[PFE
Loading...
()
], by the way, is up significantly for the second straight day).
What could be pressuring MRK is a bearish call by Steve Scala at Cowen and Company. This morning he put out a research note to clients cutting his earnings estimates from this year all the way through 2015. Scala still has an "Outperform" rating on MRK, but he's reducing sales estimates for the HPV/cervical cancer vaccine Gardasil and the allergy/asthma drug Singulair. And he thinks MRK will have to lower its earnings guidance soon because of that. On the plus side, Scala--like many other analysts--points to the nearly five percent dividend yield.
Scala owns MRK stock. He's long, not short.
Now, if only Merck had a manual on how to fix the economy, credit crisis and financial markets.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes